Hemispherx Biopharma Files Complete Response With the FDA Regarding Its Ampligen(R) New Drug Application for Chronic Fatigue Syndrome PHILADELPHIA, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") filed yesterday with the U.S. Food and Drug Administration its complete response to...

Hemispherx Biopharma and the FDA Reach Agreement on Filing Requirements for the Company's Complete Response in Support of Ampligen(R) New Drug Application for Chronic Fatigue Syndrome Treatment PHILADELPHIA, July 11, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") recently met with representatives of the U.S. Food and Drug Administration (the...